【歌礼制药-B午前股价上涨 3.32%,现报 6.54 港元,成交额 773.63 万港元】歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。ASC47 是歌礼自主研发的、脂肪靶向、超长效皮下注射选择性小分子激动剂,美国食品药品监督管理局已批准其与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外,有传闻...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.